N ‐acylethanolamine‐hydrolysing acid amidase: A new potential target to treat paclitaxel‐induced neuropathy

ConclusionsCollectively, these studies suggest that NAAA represents a promising target to treat and prevent PIPN.SignificanceThe present study demonstrates that the chemotherapeutic paclitaxel alters PEA levels in the spinal cord, whereas repeated exogenous PEA administration moderately alleviates PIPN in mice. Additionally, targeting NAAA, PEA's hydrolysing enzyme with a selective compound AM9053 reverses and prevents the PIPN via the PPAR ‐α mechanism. Overall, the data suggest that selective NAAA inhibitors denote promising future therapeutics to mitigate and prevent PIPN.

Source: European Journal of Pain - March 23, 2021 Category: Anesthesiology Authors: Wisam Toma, Martial Caillaud, Nipa H. Patel, Tammy H. Tran, Giulia Donvito, Jane Roberts, Deniz Bagdas, Asti Jackson, Aron Lichtman, David A. Gewirtz, Alexandros Makriyannis, Michael S. Malamas, M. Imad Damaj Tags: ORIGINAL MANUSCRIPT Source Type: research